JP2022519007A5 - - Google Patents

Info

Publication number
JP2022519007A5
JP2022519007A5 JP2021534126A JP2021534126A JP2022519007A5 JP 2022519007 A5 JP2022519007 A5 JP 2022519007A5 JP 2021534126 A JP2021534126 A JP 2021534126A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2022519007 A5 JP2022519007 A5 JP 2022519007A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
approximately
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066150 external-priority patent/WO2020123900A1/en
Publication of JP2022519007A publication Critical patent/JP2022519007A/ja
Publication of JP2022519007A5 publication Critical patent/JP2022519007A5/ja
Pending legal-status Critical Current

Links

JP2021534126A 2018-12-13 2019-12-13 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン Pending JP2022519007A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (2)

Publication Number Publication Date
JP2022519007A JP2022519007A (ja) 2022-03-18
JP2022519007A5 true JP2022519007A5 (enExample) 2022-12-22

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534126A Pending JP2022519007A (ja) 2018-12-13 2019-12-13 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン

Country Status (15)

Country Link
US (3) US11324732B2 (enExample)
EP (1) EP3893876A1 (enExample)
JP (1) JP2022519007A (enExample)
KR (1) KR20210114946A (enExample)
CN (1) CN113395966A (enExample)
AU (1) AU2019395250A1 (enExample)
BR (1) BR112021011386A2 (enExample)
CA (1) CA3123393A1 (enExample)
CL (1) CL2021001554A1 (enExample)
IL (1) IL283920A (enExample)
MX (1) MX2021007063A (enExample)
SG (1) SG11202106344SA (enExample)
TW (1) TWI784220B (enExample)
WO (1) WO2020123900A1 (enExample)
ZA (1) ZA202104786B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
BR112023021257A2 (pt) * 2021-04-15 2023-12-12 Neurocrine Biosciences Inc Métodos para a administração combinada de deutetrabenzina e um cyp2d6
WO2022221551A1 (en) * 2021-04-15 2022-10-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243B2 (en) * 2009-06-24 2016-09-29 Egalet Ltd Controlled release formulations
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Similar Documents

Publication Publication Date Title
Crosby et al. Amantadine in Parkinson's disease
JP2022519007A5 (enExample)
IL274943B2 (en) Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases
JP7475398B2 (ja) 医学療法におけるセマグルチド
JP7436524B2 (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
JP2019524897A5 (enExample)
JP2018513188A5 (enExample)
JP2022536687A5 (enExample)
JP2022521233A5 (enExample)
Gupta et al. Comparative evaluation of propofol versus dexmedetomidine infusion for hypotensive anesthesia during functional endoscopic sinus surgery: a prospective randomized trial
JP2023548429A5 (enExample)
Servais et al. FIREFISH part 2: efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)
JP2022553888A5 (enExample)
CN104013638A (zh) 当药黄素及其衍生物的用途
JPH08512311A (ja) 慢性疲労症候群治療用ヒ素医薬
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP7016880B2 (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および/または近視進行抑制剤
JP2021532165A5 (enExample)
WO2013172339A1 (ja) 腹圧性尿失禁予防剤及び/又は治療剤
JP2024531799A5 (enExample)
CA2840521C (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
CN114588164A (zh) 瑞马唑仑在预防围术期低体温和寒战中的应用
CN115768430A (zh) 伴随代谢异常的疾病或综合征中的肌力下降症状的改善剂或预防剂
US20230398090A1 (en) Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof
US11400060B2 (en) Use of ketamine in the treatment of cachexia